Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bempedoic acid + ezetimibe + rosuvastatin
- Development stage
- Phase 1
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bempedoic acid/ezetimibe/rosuvastatin is an oral fixed-dose triple combination therapy developed by Daiichi Sankyo for the treatment of hypercholesterolemia and mixed dyslipidemia. This combination leverages three distinct, complementary mechanisms to lower LDL cholesterol: bempedoic acid inhibits ATP citrate lyase upstream of the statin pathway; ezetimibe inhibits the NPC1L1 transporter to reduce intestinal cholesterol absorption; and rosuvastatin inhibits HMG-CoA reductase to decrease hepatic cholesterol synthesis. The formulation is primarily intended for patients with primary hypercholesterolemia or mixed dyslipidemia who require intensive LDL-C lowering beyond what is achievable with dual therapy or standard statin regimens. It is currently being evaluated in Phase 1 bioequivalence studies comparing the fixed-dose combination tablet against the co-administration of its individual reference components.
- Other names
- bempedoic acid/ezetimibe/rosuvastatin FDCbempedoic acid + ezetimibe + rosuvastatin fixed-dose combination
02
Targets
ACLY (ATP-citrate synthase)OATP1B1 (Organic anion transporting polypeptide 1B1)SLCO1B3 (Organic anion transporting polypeptide 1B3)NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on bempedoic acid + ezetimibe + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bempedoic acid + ezetimibe + rosuvastatin.